ePHex: a phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria

BACKGROUND: Primary hyperoxalurias (PHs) are rare genetic diseases that increase the endogenous level of oxalate, a waste metabolite excreted predominantly by the kidneys and also the gut. Treatments aim to improve oxalate excretion, or reduce oxalate generation, to prevent kidney function deteriora...

Descripción completa

Detalles Bibliográficos
Autores principales: Ariceta, Gema, Collard, Laure, Abroug, Saoussen, Moochhala, Shabbir H., Gould, Edward, Boussetta, Abir, Ben Hmida, Mohamed, De, Sudarsana, Hunley, Tracy E., Jarraya, Faical, Fraga, Gloria, Banos, Ana, Lindner, Elisabeth, Dehmel, Bastian, Schalk, Gesa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763141/
https://www.ncbi.nlm.nih.gov/pubmed/35552824
http://dx.doi.org/10.1007/s00467-022-05591-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763141/
https://www.ncbi.nlm.nih.gov/pubmed/35552824
http://dx.doi.org/10.1007/s00467-022-05591-5

Ejemplares similares